Tinengotinib
Novel compound combining FGFR inhibition with CDK4/6 and Aurora A. Triple FGFR + CDK + Aurora — overcomes multiple resistance nodes
Description
Scientific Overview: Novel compound combining FGFR inhibition with CDK4/6 and Aurora A. Triple FGFR + CDK + Aurora — overcomes multiple resistance nodes
Mechanism of Action: Pan-FGFR + CDK Inhibitor
Purity: ≥99% | Molecular Formula: N/A
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Pan-FGFR + CDK Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | |
| CAS Number |
